BRING THIS TO YOUR DOCTOR · GREY PEPTIDES

Edotreotide

Also called: DOTATOC; Ga 68 DOTATOC; 177Lu-edotreotide; Gallium Ga 68 edotreotide

What it is

DOTATOC: a somatostatin analogue for neuroendocrine tumour PET (Ga 68 DOTATOC, approved 2019) and investigational lutetium-177 therapy.

Approval status

FDA Approved. Ga 68 DOTATOC (gallium Ga 68 edotreotide) injection, NDA 210828, approved August 21, 2019 for PET of somatostatin receptor-positive neuroendocrine tumours in adults and children (Drugs@FDA via openFDA and the label effective December 8, 2021, read October 3, 2026). Lutetium-177 edotreotide is investigational.

Dosing, as printed in the page's Recommended Dosing box

Manufacturer's recommended dosing (FDA label)

From the prescribing information. Other doses studied, if any, are in the full dosing data below.

Protocol and source	Dose	Frequency	Duration	Route
Label: Ga 68 DOTATOC imaging, adults **[Approved label]** Ga 68 DOTATOC (gallium Ga 68 edotreotide) injection US prescribing information, section 2 (DailyMed set c4d185c3, effective December 8, 2021)	148 MBq (4 mCi)	Single bolus	Once, imaging at 55–90 minutes	Intravenous
Label: Ga 68 DOTATOC imaging, children **[Approved label]** Ga 68 DOTATOC (gallium Ga 68 edotreotide) injection US prescribing information, section 2 (DailyMed set c4d185c3, effective December 8, 2021)	1.59 MBq/kg (11.1 to 111 MBq)	Single bolus	Once	Intravenous

Used in human trials

No manufacturer dose exists for this use: these are amounts given in published trials, not recommendations.

Protocol and source	Dose	Frequency	Duration	Route
COMPETE treatment (2026) **[Human study]** PMID 42392118	About 7.5 GBq lutetium-177 edotreotide	Every 3 months	Up to 4 cycles	Intravenous

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for "research use only" are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

Key human evidence

The first 3 of the 16 human studies carded on the page (17 study cards in all):

- **Lutetium-177 edotreotide meta-analysis** (Human, 2026). Across eight studies in advanced neuroendocrine tumours, patients with gastroenteropancreatic tumours had objective response 34%, disease control 78%, median PFS 24.9 months and median OS 44.8 months; grade 3/4 toxicity was rare, but heterogeneity was high. **PMID 41204752**
- **Gallium-68 DOTATOC vs FDG PET** (Human, 2018). In 36 patients, sensitivity was 88% for gallium-68 DOTATOC, 41% for FDG PET and 53% for conventional workup, with specificity of 100%, 100% and 68%. **PMID 28735662**
- **LEVEL trial design** (Human, 2025). The randomised LEVEL trial (NCT05918302) is testing whether lutetium-177 edotreotide improves survival and quality of life in neuroendocrine tumours of the lung and thymus. **PMID 40186126**

Interactions

From the FDA label's drug-interaction section (UIHC PET Imaging Center. Ga 68 DOTATOC (gallium Ga 68 edotreotide) injection US prescribing information, section 7. DailyMed version of December 8, 2021, read October 3, 2026):

- With long-acting somatostatin analogues: compete for the same receptors; image just before the next long-acting dose (FDA label)
- With short-acting somatostatin analogues: can be used up to 24 hours before imaging (FDA label)

Side effects and cautions

Reported side effects	Contraindications and cautions
• Grade 3/4 toxicity rarely reported with lutetium-177 edotreotide • In COMPETE, diarrhoea and nausea (each 36%) and asthenia (33%) were the commonest treatment-related effects of lutetium-177 edotreotide • Everolimus caused more grade 3-4 effects than the radiotherapy in COMPETE (40% against 18%)	• Radiation risk • Hypersensitivity reactions • Risk of image misinterpretation

Five questions to ask

1. Is Edotreotide right for me, and is the labelled dose on this sheet right for my weight, age, kidney and liver function?
2. Here are the medicines and supplements I take. Do any of them interact with Edotreotide? This sheet lists the interactions on record.
3. Which side effects should make me stop and call you, for example grade 3/4 toxicity rarely reported with lutetium-177 edotreotide?
4. Do any of the cautions on this sheet apply to me, such as: Radiation risk?
5. What should we check before I start and while I am on it (blood tests, blood pressure, weight), and how often?

Grey Peptides is a vendor-neutral encyclopedia: it sells nothing and names no seller. This sheet is educational, not medical advice, and is not a prescription.